2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Fractures, Spontaneous: new trials by email Literature Review of Fractures, Spontaneous trials Research Report on Fractures, Spontaneous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts Denosumab (Xgeva) - Bone Cyst Aneurysmal, Pathological Fracture | Phase 1 / Phase 2 | Completed | Peking University People's Hospital | 6 | 2014-01-01 | 2018-01-30 |
| Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration - Refractory Multiple Myeloma | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2011-11-01 | 2019-08-28 |
Amyloidosis (1) · Anemia (1) · Bone Cysts, Aneurysmal (1) · Bone Diseases, Metabolic (1) · Hematologic Neoplasms (1) · Hypercalcemia (1) · Multiple Myeloma (1) · Neoplasms (1) · Osteolysis (1) · Paraproteinemias (1) · Recurrence (1) · Renal Insufficiency (1)
Bone Diseases (2) · Fractures, Bone (2) · Musculoskeletal Diseases (2) · Wounds and Injuries (2) · Blood Protein Disorders (1) · Bone Cysts (1) · Bone Resorption (1) · Calcium Metabolism Disorders (1) · Cardiovascular Diseases (1) · Cysts (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1)
ARQ 197 (1) · Denosumab (1) · Surgical Procedures, Operative (1)
National Cancer Institute (NCI) (1) · Peking University People's Hospital (1)
United States (1)
Robert Orlowski (1)
N01CM00039 (1), P30CA016672 (1), U01CA062461 (1)